6-K 1 tm2429142d1_6k.htm FORM 6-K

 

 

 

UNITED STATES

 

SECURITIES AND EXCHANGE COMMISSION

 

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of November 2024

 

Commission File Number: 001-41937

 

Psyence Biomedical Ltd.

 

(Translation of registrant’s name into English)

 

121 Richmond Street West
Penthouse Suite 1300
Toronto, Ontario M5H 2K1

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

x Form 20-F  ¨ Form 40-F

 

 

 

 

 

 

EXHIBIT INDEX

 

Exhibit   Description
     
4.1   Form of Common Share Purchase Warrant
10.1   Termination Agreement, by and between the Company and the Signatories thereto, dated November 21, 2024.
99.1   Press Release, dated November 19, 2024, Announcing Effective Date of Share Consolidation.
99.2   Press Release, dated November 20, 2024, Announcing the Favorable Result of Nasdaq Listing Qualifications Hearing
99.3   Investor Presentation, dated November 2024.

   

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

Dated: November 22, 2024 

 

Psyence Biomedical Ltd.  
     
By: /s/ Dr. Neil Maresky  
Name:  Dr. Neil Maresky  
Title: Chief Executive Officer and Director